Muscle-Specific Promoters May Be Necessary for Adeno-Associated Virus-Mediated Gene Transfer in the Treatment of Muscular Dystrophies
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Recombinant adeno-associated virus (rAAV) vectors allow efficient gene transfer and expression in the muscle; therefore, rAAVs represent a potential gene therapy vector for muscular dystrophies. For further investigations, we used a mouse muscular dystrophy model (gsg(-/-) mice) gamma-sarcoglycan, a subunit of the dystrophin-glycoprotein complex, is missing. gsg(-/-) mice develop progressive dystrophy representative of a severe human phenotype disease. We previously showed high levels and stable expression of gamma-sarcoglycan in myofibers after direct muscle injection into gsg(-/-) mice of a recombinant AAV vector (AAV.dMCK.gSG) carrying the gamma-sarcoglycan cDNA driven by a muscle-specific promoter (truncated version of muscle creatine kinase). Here, we show that when gamma-sarcoglycan expression is driven by the ubiquitous cytomegalovirus (CMV) promoter (AAV.CMV.gSG), lower levels of transgene expression are observed and are associated with a humoral response to gamma-sarcoglycan. When using an rAAV vector, expressing the highly immunogenic product gamma-galactosidase under the CMV promoter (AAV.CMV.LacZ), we measured a strong cellular and humoral immune response to the transgene after intramuscular injection into gsg(-/-) mice. This study suggests that restriction of transgene expression to the muscle is an important criterion for the treatment of muscular dystrophies and will aid in the design of protocols for gene therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition to systemic immune suppression, preclinical studies pointed out the role of tissue-specific promoters in reducing immune responses against delivered transgene [232, 233].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [232]
Citations
Cites
Dendritic cells and the control of immunity
Banchereau, J., & Steinman, R. M. (1998) · Nature · doi:10.1038/32588 · Cited by 14,336 · cited 2×
“To appreciate the contribution of endogenous transduction of antigen-presenting cells (APCs) by the rAAV, we compared an rAAV expressing g -sarcoglycan under the control of a muscle-specific promoter (truncated version of the muscle creatine kinase [MCK]) and the ubiquitous CMV promoter.”
Characteristics of a human cell line transformed by DNA from human adenovirus type 5
Graham, F. L., Russell, W. C., Smiley, J., & Nairn, R. (1977) · Journal of General Virology · doi:10.1099/0022-1317-36-1-59 · Cited by 4,793
Yang, Y., Li, Q., Ertl, H. C., & Wilson, J. M. (1995) · Journal of Virology · doi:10.1128/jvi.69.4.2004-2015.1995 · Cited by 1,032 · cited 1×
“These vectors usually exhibit loss of expression 3 to 4 weeks after administration (Yang et al ., 1995b, 1996b; Tripathy et al ., 1996).”
Self-citationKay, M. A., Manno, C. S., Ragni, M. V., Larson, P. J., Couto, L. B., McClelland, A., Glader, B., Chew, A. J., J Tai, S., Herzog, R. W., et al. (2000) · Nature Genetics · doi:10.1038/73464 · Cited by 1,022
Xiao, X., Li, J., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.11.8098-8108.1996 · Cited by 912 · cited 1×
“CMV. LacZ has been shown to allow long-term expression (greater than 1 year) of the marker protein without eliciting a cellular or humoral immune response to the vector-transduced cells (Xiao et al ., 1996; Fisher et al ., 1997).”
Recombinant adeno-associated virus for muscle directed gene therapy
Fisher, K. J., Jooss, K., Alston, J., Yang, Y., Haecker, S. E., High, K., Pathak, R., Raper, S. E., & Wilson, J. M. (1997) · Nature Medicine · doi:10.1038/nm0397-306 · Cited by 654
Self-citationTripathy, S. K., Black, H. B., Goldwasser, E., & Leiden, J. M. (1996) · Nature Medicine · doi:10.1038/nm0596-545 · Cited by 628 · cited 1×
“These vectors usually exhibit loss of expression 3 to 4 weeks after administration (Yang et al ., 1995b, 1996b; Tripathy et al ., 1996).”
Sigal, L. J., Crotty, S., Andino, R., & Rock, K. L. (1999) · Nature · doi:10.1038/18038 · Cited by 578
Fisher, K. J., Gao, G. P., Weitzman, M. D., DeMatteo, R., Burda, J. F., & Wilson, J. M. (1996) · Journal of Virology · doi:10.1128/jvi.70.1.520-532.1996 · Cited by 547 · cited 1×
“Transfection was carried out by the standard calcium phosphate precipitation method. rAAV vector preparations used in this study were purified by the CsCl gradient centrifugation process as described earlier (Fisher et al ., 1996).”
Self-citationDuan, D., Sharma, P., Yang, J., Yue, Y., Dudus, L., Zhang, Y., Fisher, K. J., & Engelhardt, J. F. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8568-8577.1998 · Cited by 522
Research works printed but not linked: 5
- ABINA M.A., 1996, Gene Ther., 3, 212
- BROCKSTEDT D.G., 1999, J. Appl. Biomater., 92, 67
- MCNALLY E.M., 1996, Am. J. Hum. Genet., 59, 1040
- YANG Y., 1996, Gene Ther., 3, 137
- YANG Y., 1996, Gene Ther., 3, 412
Cited by
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
“The role of tissue-specific promoters in reducing or abrogating immune responses to the transgene product has been demonstrated in the setting of animal models of muscular dystrophy.(136,137) The use of tissue-specific micro RNA elements to detarget transgene expression in DCs, first used in the context of lentiviral…”
Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy
Duan, D. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.011 · Cited by 489
Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy
Jooss, K., & Chirmule, N. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302037 · Cited by 277
Self-citationRegulatable gene expression systems for gene therapy applications: progress and future challenges
Goverdhana, S., Puntel, M., Xiong, W., Zirger, J. M., Barcia, C., Curtin, J. F., Soffer, E. B., Mondkar, S., King, G. D., Hu, J., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.03.022 · Cited by 283
“The degree of immune response to a viral vector can be a consequence of one or more factors that include the method and route of vector delivery at the target site [208], cell-type-specific gene expression [209], and immunogenicity of the vector”
BackgroundSalva, M. Z., Himeda, C. L., Tai, P. W., Nishiuchi, E., Gregorevic, P., Allen, J. M., Finn, E. E., Nguyen, Q. G., Blankinship, M. J., Meuse, L., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300027 · Cited by 232
Metadata
- Authors
- Cordier, L., Gao, G.-P., Hack, A. A., McNally, E. M., Wilson, J. M., Chirmule, N., & Sweeney, H. L.
- Affiliations
- University of Pennsylvania (US)
- Institute for Human Gene Therapy, University of Pennsylvania, Philadelphia, PA 19104
- University of Chicago (US)
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2001-01-20
- Volume
- 12
- Issue
- 2
- Pages
- 205-215
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2174994066
- Cited by
- 152
- References
- 42
- Citations by year
- 2026: 5 · 2025: 3 · 2024: 3 · 2023: 4 · 2022: 1 · 2021: 2 · 2020: 2 · 2019: 2 · 2018: 4 · 2017: 3 · 2015: 3 · 2014: 5 · 2013: 3 · 2012: 7
- FWCI
- 7.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.liebertpub.com/nv/resources-tools/text-and-data-mining-policy/121/ (tdm)
- Locations
- Human Gene Therapy (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR/NS43648)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus vectors, gene therapy, muscular dystrophy, muscle-specific promoter, cytomegalovirus promoter, gamma-sarcoglycan, dystrophin-glycoprotein complex, humoral immune response, intramuscular injection, gene transfer
- MeSH terms
- Dependovirus, Animals, Antigen-Presenting Cells, beta-Galactosidase, Creatine Kinase, Cytoskeletal Proteins, Dendritic Cells, Genetic Vectors, Humans, Immunoenzyme Techniques, Macrophages, Membrane Glycoproteins, Mice, Inbred C57BL, Mice, Mutant Strains, Muscular Dystrophies, Promoter Regions, Genetic, T-Lymphocytes, Cytotoxic, Transduction, Genetic, Blotting, Western, Dystrophin, Gene Transfer Techniques, Muscle, Skeletal, Sarcoglycans, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Muscle-Specific Promoters May Be Necessary for Adeno-Associated Virus-Mediated Gene Transfer in the Treatment of Muscular Dystrophies. https://app.cochat.ai/papers/10.1089/104303401750061267
- The paper
- Cordier, L., Gao, G.-P., Hack, A. A., McNally, E. M., Wilson, J. M., Chirmule, N., & Sweeney, H. L. (2001). Muscle-Specific Promoters May Be Necessary for Adeno-Associated Virus-Mediated Gene Transfer in the Treatment of Muscular Dystrophies. Human Gene Therapy. https://doi.org/10.1089/104303401750061267
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.